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Abstract
Post-weaning diarrhea and edema disease caused by F18 fimbriated E. coli are
important diseases in newly weaned piglets and lead to severe production losses in
farming industry. Protective treatments against these infections have thus far limited
efficacy. In this study we generated nanobodies directed against the lectin domain
of the F18 fimbrial adhesin FedF and showed in an in vitro adherence assay that
four unique nanobodies inhibit the attachment of F18 fimbriated E. coli bacteria to
piglet enterocytes. Crystallization of the FedF lectin domain with the most potent
inhibitory nanobodies revealed their mechanism of action. These either competed
with the binding of the blood group antigen receptor on the FedF surface or induced
a conformational change in which the CDR3 region of the nanobody displaces the
D0-E loop adjacent to the binding site. This D0-E loop was previously shown to be
required for the interaction between F18 fimbriated bacteria and blood group
antigen receptors in a membrane context. This work demonstrates the feasibility of
inhibiting the attachment of fimbriated pathogens by employing nanobodies
directed against the adhesin domain.
Introduction
In farming industry enterotoxigenic Escherichia coli (ETEC) and Shiga toxin
producing E. coli (STEC) are important pathogens [1, 2] causing serious mortality
and severe production losses [3]. Common to both classes of pathogenic E. coli is
the presence of two crucial virulence factors: (1) adherence factors (often
OPEN ACCESS
Citation: Moonens K, De Kerpel M, Coddens A,
Cox E, Pardon E, et al. (2014) Nanobody Mediated
Inhibition of Attachment of F18 Fimbriae
Expressing Escherichia coli. PLoS ONE 9(12):
e114691. doi:10.1371/journal.pone.0114691
Editor: Eric Cascales, Centre National de la
Recherche Scientifique, Aix-Marseille Universite´,
France
Received: September 7, 2014
Accepted: November 12, 2014
Published: December 11, 2014
Copyright:  2014 Moonens et al. This is an
open-access article distributed under the terms of
the Creative Commons Attribution License, which
permits unrestricted use, distribution, and repro-
duction in any medium, provided the original author
and source are credited.
Data Availability: The authors confirm that all data
underlying the findings are fully available without
restriction. All relevant data are within the paper
and its Supporting Information files. All PDB files
are available from the PDB database (accession
numbers 4W6W, 4W6X and 4W6Y).
Funding: K.M. was a doctoral fellow of the Fonds
voor Wetenschappelijk Onderzoek (FWO) –
Vlaanderen. H.R. is supported by a VIB Young PI
project grant and the Odysseus program of the
FWO-Vlaanderen. E.P. is supported by grant 7/40
of the Interuniversity Attraction Poles (IAP)
Program of the Belgian Science Policy Office. The
authors are grateful to the beamline staff of the
Swiss Light Source (SLS; Switzerland), Diamond
Light Source (England) and Soleil (France) for
support with data collection and processing. This
research was granted by FWO project G030411N
and equipment grant UABR/09/005 from the
Hercules Foundation. The funders had no role in
study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing Interests: Henri De Greve is co-
inventor on a PCT application regarding the use of
plant-produced Fc-nanobody fusions for passive
immunization against animal ETEC infections. This
does not alter the authors’ adherence to PLOS
ONE policies on sharing data and materials.
PLOS ONE | DOI:10.1371/journal.pone.0114691 December 11, 2014 1 / 20
fimbriae) in order to mediate the attachment to specific receptors, usually glycans,
followed by colonization of the intestinal tract and (2) the production of one or
multiple toxins that induce disease symptoms [2]. In piglets ETEC and STEC
strains expressing F18 fimbriae are associated with respectively post-weaning
diarrhoea and edema disease [4, 5]. After the initial adherence step via the F18
fimbriae ETEC strains produce and secrete the heat-labile (LT) and/or heat-stable
enterotoxins (ST), thereby stimulating the secretion of electrolytes and water and
resulting in dehydration of the enterocytes and watery diarrhoea [6, 7]. F18
positive STEC strains instead produce the Shiga toxin Stx2e, which acts by
depurination of a specific adenine from the 28S ribosomal RNA, efficiently
shutting down protein synthesis and killing the affected cells that express the
globotetraosylceramide receptor [8]. Damage to the vascular endothelium
eventually results in edema, hemorrhage and microthrombosis, and will be fatal in
90% of all STEC affected animals [9]. STEC lack a secretory mechanism for Stx
and the release of Stx occurs through lambdoid phage-mediated lysis [10].
F18 fimbriae are assembled by a dedicated machinery, the chaperone/usher
pathway, that is distributed among genera of the phyla Proteobacteria,
Cyanobacteria, and Deinococcus-Thermus. Essential to the CU pathway are a
periplasmic chaperone protein and an outer membrane pilus assembly platform,
termed usher [11]. Fimbrial subunits or pilins are stabilized by the chaperone and
complemented in the final quaternary structure by an N-terminal donor strand of
the following subunit. The usher both acts as a building platform and anchors the
fimbriae to the cell surface [12]. The two-domain tipsubunit often harbors the
adhesive properties and thus determines the host tropism of the bacteria [13]. It
features a typical two-domain organization comprising an N-terminal receptor-
binding domain linked to a C-terminal pilin domain that forms the connection to
the fimbrial shaft. F18 fimbriae are comprised of the major subunit FedA [14], the
minor subunit FedE and the tip-adhesin FedF [15], which binds to glyco-
sphingolipids having A/H blood group type 1 core antigens (H: Fuca2Galb3
GlcNAcb3Galb4Glc; A: GalNAca3(Fuca2)Galb3GlcNAcb3Galb4Glc) that are
present on enterocytes of the small intestine [16].
Previously we elucidated the co-complex structure of the FedF lectin domain
with the blood group A type 1 hexasaccharide [17]. The carbohydrate ligand is
interacting in an extended conformation at a shallow binding site on the FedF
surface via an extensive hydrogen bond network. In addition we identified a
polybasic loop, adjacent to the blood group binding site, which was shown a
prerequisite for enterocyte binding although not required for glycan recognition
in solution. Upon interaction of FedF with blood group antigen carrying
sphingolipids, two positively charged lysine residues on this so called D0-E loop,
identified by site-directed mutagenesis, we predicted to come into close proximity
to the membrane. Both were shown be required for the FedF–glycosphingolipid
interaction in proximity of the lipid bilayer and are expected to provide selectivity
towards membrane-associated A/H determinants whilst evading binding to
soluble A/H antigens on glycoproteins present in mucosal secretions.
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After birth, suckling piglets are protected from F18+ STEC by specific
antibodies in the sow milk. Vaccination of the sow can enhance the protection
and so far several maternal vaccines are available on the market [18]. At weaning
this lactogenic immunity is lost and together with the stress associated with the
weaning period the piglet will become highly vulnerable to infections by enteric
pathogens. Previously, antibiotics were widely employed as prophylaxis treatment
during piglet weaning, but the recent ban of such therapy in the European Union
has urged the development of alternative treatments. These include the
administration of zinc oxide, organic acids, probiotics, prebiotics, antibodies and
vaccines [1, 18, 19], but none provide a satisfying protection against ETEC and
STEC caused disease. In addition, F18 fimbriae have a limited capability in
stimulating the immune response after oral vaccination [18, 20].
In this study we identified specific nanobodies that could block attachment
mediated by F18 producing E. coli. The inhibitory mechanism of four unique
nanobodies that completely abolished adherence was investigated and shown to
differ amongst them. Either the binding was prevented by competing for the
carbohydrate binding site or a conformational change was induced in the critical
D0-E loop. In the near future these nanobodies will be expressed in plants and
used as a feed supplement against the economically important ETEC and STEC
infections.
Materials and Methods
Generation and selection of anti-FedF15–165 nanobodies
The complete protocol of nanobody generation and selection by panning has
recently been described thoroughly [21]. In short, a llama was immunized six
times with 330 mg of purified FedF15–165 (see below) over a period of 6 weeks.
Lymphocytes from the anti-coagulated blood of the immunized llama were
employed to prepare cDNA that served as a template to amplify the open reading
frames coding for the variable domains of the heavy chain antibodies. The PCR
fragments were subsequently ligated into the pHEN11 phage display vector
referred as pHEN4C in Conrath et al. [22]. The pHEN11 contains the
chloramphenicol acetyltransferase gene replacing the beta-lactamase gene present
in pHEN4. After transformation into E. coli TG1 cells, FedF15–165-specific
nanobodies were selected by phage display [23]. After selection, phages were
eluted by incubating the FedF15–165-coated wells with with 100 mM triethylamine
(pH 10) for 10 min. After two rounds of panning, 96 individual colonies were
selected and grown in 2X TY medium supplemented with chloramphenicol
(25 mg/ml) and induced with 1 mM isopropyl b-D-1-thiogalactopyranoside
(IPTG, Thermo Scientific)) for expression of soluble periplasmic nanobodies. The
periplasmic extract was next subjected to an ELISA to confirm the selected
nanobodies are indeed recognizing the purified FedF15–165. After the selection
rounds the nanobody genes were PCR amplified using primers Lumio6 (59-
GGGGACCACTTTGTACAAGAAA GCTGGGTATTAGTGATGGTGATG-
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GTGGTGTGAGGAGACGGTGACCTGGGTCCCCTGGCC-39) and Lumio7 (59-
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAAGAAGGAGATATACCATG
AAATACCTATTGCCTACGGCAGCCGCTGGATTGT-39) to introduce a His-tag
at the C-terminus of the nanobodies. The resulting PCR fragments were inserted
in the pDONR221 Gateway entry vector (Invitrogen) using the BP clonase enzyme
(Invitrogen). Subsequently, the resulting plasmids were recombined into the
pDESTR4-R3 plasmid, together with the araC activator and the pBAD promoter
(pGV5159) and the green fluorescent protein encoded by the gfp gene (pENT105),
in a MultiGateway reaction using the LR plus clonase enzyme (Invitrogen). The
gfp gene was amplified from a GFP positive strain [24]. After transformation in
CaCl2-competent E. coli DH5a, colonies were selected on LB-agar plates
containing ampicillin (100 mg/ml). Transformants were PCR screened with
primers Aida9b (59-GCGAAATTAATACGACTCACTATA-39) and pET-rv (59-G-
GTTATGCTAG TTATTGCTCAGCG-39).
Expression, isolation and purification of the different FedF binding
nanobodies
An overnight preculture of E. coli WK6 cells harboring the pDESTR4-R3 vector
with insert encoding for 6xHis-tagged nanobodies was used to inoculate lysogeny
broth (LB) media [25] (1:100) supplemented with 100 mg/ml ampicillin. Bacterial
cells were grown at 310 K, induced at OD600 nm of ,0.8 with arabinose (0.2%),
100 mg/ml ampicillin was added and the cell cultures incubated overnight at
310 K while shaking. The cell pellet was harvested by centrifugation at 6238 rcf for
15 minutes at 277 K. Extraction of periplasmic proteins was performed by
suspending 1 g of wet cell pellet in 4 ml of 20 mM Tris-HCl pH 8, 2 mM EDTA,
30% (w/v) sucrose buffer. The mixture was left on ice for 30 minutes, centrifuged
at 17418 rcf for 20 minutes at 277 K, and the cell pellet resuspended in 20 mM
Tris-HCl pH 8.0 (4 ml/g pellet). The mixture was incubated half an hour on ice
and centrifuged at 17418 rcf for 20 minutes at 277 K. The supernatant (5
periplasmic extract) was collected and kept at 277 K until further purification.
To purify the different nanobodies 1 M NaCl was added to the filtrated
periplasmic extract and subsequently loaded on a pre-packed Ni-NTA column
(GE Healthcare) equilibrated in 20 mM Tris-HCl pH 8, 1 M NaCl. The column
was washed with Tris-HCl pH 8, 1 M NaCl until all unbound contaminants were
removed and eventually bound nanobodies were eluted by applying a stepwise
gradient to 1 M imidazole. Elution fractions were analysed on purity with SDS-
PAGE and dialyzed into the appropriate buffer solution.
In vitro villous adhesion assay
F18 seronegative pigs, weaned at the age of 3–4 weeks, were transported to the
stables of the Faculty of Veterinary Medicine (UGent). Upon arrival, they were
orally given colistin (promycine pulvis; 1000 iu/mg; doses 0.1 g/kg) for 3
successive days to prevent or clear an infection with F18-positive E. coli which
Inhibitory Nanobodies against F18 Fimbriae
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might occur at weaning. Pigs were euthanized by an overdose of Nembutal
(60 mg/kg intravenously). The villi were prepared as previously described [26].
Briefly, a 20 cm long intestinal segment was excised of the mid jejunum at the
moment of slaughter and washed twice with Krebs–Henseleit buffer (0.12 M
NaCl, 0.014 M KCl, 0.001 M KH2PO4, 0.025 M NaHCO3, pH 7.4) and once
with the same buffer containing 1% (v/v) formaldehyde for 30 min at 4 C˚.
Subsequently, the villi were gently scraped from the mucosa with a glass slide and
stored in Krebs–Heinseleit buffer at 4 C˚. When used for testing, villi were
resuspended in PBS supplemented with 1% (w/v) D-mannose (Fluka) to prevent
adhesion by type 1 pili.
An in vitro adhesion assay on small intestinal villous enterocytes was performed
as previously described [27]. The wild type F18-positive E. coli strain 107/86 was
mixed together with either 16 phosphate-buffered saline (PBS) buffer or one of
the twelve different FedF-specific nanobodies (final concentration of 10 mg/ml)
and tested for binding to villi by adding 46108 bacteria to an average of 50 villi in
a total volume of 500 ml of PBS, followed by incubation at room temperature for
1 h while being gently shaken. Villi were examined by phase-contrast microscopy
at a magnification of 6006 and the number of bacteria adhering along 50 mm
brush border was quantitatively evaluated by counting the number of adhering
bacteria at 20 randomly selected places, after which the mean bacterial adhesion
was calculated. Adhesion tests were performed in triplicate on intestinal villi of
two different piglets.
Expression and purification of FedF15–165
The N-terminal lectin domain of FedF comprising residues 15 to 165 (FedF15–165)
was over expressed and purified as earlier described [28]. In short, plasmid
pEXP62 was introduced in C43 (DE3) E. coli cells and grown in lysogeny broth
(LB) supplemented with 100 mg/ml ampicillin at 37 C˚ until the OD600 reached
1.0 and then induced with 1 mM IPTG. Induction was allowed to proceed during
3 h at 37 C˚, after which periplasmic proteins were collected by administering an
osmotic shock. To purify FedF15–165 the cleared periplasmic extract was loaded
onto a Source 30S cation exchange column equilibrated in 20 mM Tris-HCl
pH 7.5 and eluted by a NaCl gradient to 0.5 M. Elution fractions were analyzed
on purity with SDS-PAGE and dialyzed into the appropriate buffer solution.
Microscale thermophoresis (MST)
Microscale thermophoresis is an immobilization-free technique for the analysis of
biomolecules interacting in solution [29–31]. Saturation binding experiments
were performed using a NanoTemper Monolith NT.115 instrument
(NanoTemper Technologies). In MST an infrared-laser produces precise
microscale temperature gradients within thin glass capillaries that are filled with
the two binding partners. Molecules move along these temperature gradients and
any change of the hydration shell of proteins due to changes in their primary,
Inhibitory Nanobodies against F18 Fimbriae
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secondary, tertiary and/or quaternary structure affects the thermophoretic
movement. FedF15–165 was fluorescently labeled via surface exposed amine groups
with NT647 and the concentration was kept constant (150 nM) while varying the
concentration of nanobodies, ranging from 1.28 mM to 0.04 nM. Afterwards 3–
5 ml of the samples were loaded into glass capillaries (Monolith NT TM
Capillaries) and the thermophoresis analysis was performed (LED 100%, IR laser
50%). The interaction was measured in HBS buffer (20 mM HEPES pH 7.4,
150 mM NaCl, 0.005% Tween20) and data was analyzed using the NT Analysis
software (NanoTemper Technologies).
Formation, crystallization and structure determination of the
complexes between FedF15–165 and different inhibitory nanobodies
Complexes between FedF15–165 and the different nanobodies were obtained by
adding an excess of FedF15–165 to the appropriate nanobody and subsequently load
the mixture on a pre-packed Ni-NTA column (GE Healthcare). The FedF15–165-
nanobody complexes will be retained on the column as only the nanobodies
possess a C-terminal 66 His-tag. Elution of the complexes was performed by
stepwise addition of 1 M imidazole.
The FedF15–165-NbFedF6, FedF15–165-NbFedF7 and FedF15–165-NbFedF9 co-
complexes were dialyzed to 20 mM HEPES pH 7.5, 50 mM NaCl; concentrated
and set up for crystallization (1:1 stoichiometry protein/well solution). Initial hits
were further optimized to conditions that produced well-diffracting crystals.
FedF15–165-NbFedF6 (16 mg/ml) readily crystallized against a solution containing
160 mM NaCl, 80 mM Bis-Tris pH 5.5 and 20% PEG-3350; FedF15–165-NbFedF7
(7 mg/ml) against a solution 1 M (NH4)2 SO4, 90 mM Na-citrate pH 4.0; and
finally FedF15–165-NbFedF9 (10 mg/ml) produced good diffracting crystals when
set up against 2 M (NH4)2 SO4, 5% PEG-400 and 100 mM MES pH 6.5. The
crystals were flash-cooled to 100 K in their crystallization solution supplemented
with 15% glycerol for data collection. A single wavelength data was collected and
data were processed with XDS and Xscale of XDS [32] and prepared with
Pointless and Scala from the CCP4 suite [33]. Data were phased by molecular
replacement [33] using coordinates of the previously determined FedF15–165
structure (PDB code 4B4P) and a random nanobody obtained from the PDB
database (PDB code 2X1O). The models were further improved using the graphics
program COOT [34] and refined using Refmac with TLS refinement [33] against
the native dataset. Crystal parameters and data processing statistics for all
structures are summarized in Table 1. The electron density maps of the
interaction interface are shown in S5 Figure.
Surface plasmon resonance measurements
SPR experiments were carried out using a Biacore T200 instrument (GE
healthcare). The surface of a CM5 sensor chip was activated with a 1:1 mixture of
0.1 M N-hydroxysuccinimide (NHS) and 0.4 M 1-ethyl-3-(3-dimethylamino-
Inhibitory Nanobodies against F18 Fimbriae
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propyl) carbodiimide hydrochloride (EDC). After activation of the surface the
glycoconjugate human serum albumin-blood group A type 1 hexaose (HSA-A6-1)
(10 mg/ml) (IsoSep AB, Sweden) in 10 mM sodium acetate, pH 4 was injected to
flow cell 2 (FC2) to be immobilized on the sensor surface via primary amine
groups. As a control the same amount of HSA was immobilized on FC1. Residual
unreacted active ester groups were blocked with 1 M ethanolamine-HCl, pH 8.5.
A constant amount of FedF15–165 (25 mM) was either alone or mixed with two-
fold excess of the different nanobodies (50 mM) in HBS buffer (10 mM HEPES,
150 mM NaCl, 1 mM EDTA, 0.005% Tween20, pH 7.4) injected over the chip
surface at a flow rate of 10 ml/min at 25 C˚.
Table 1. Data collection, crystal parameters, and refinement statistics for the co-complexes of FedF15-165 with
NbFedF9, NbFedF6 and NbFedF7.
FedF15-165-NbFedF9 FedF15-165-NbFedF6 FedF15-165-NbFedF7
Wavelength 1.00 0.98 0.98
Beamline SLS PX III Diamond IO4 Soleil Proxima 2
Space group C 2 2 21 P 32 2 1 P 21 21 21
a, b, c (A˚) 52.6, 103.0, 114.5 101.4, 101.4, 62.8 30.3, 78.6, 108.9
a, b, g (˚) 90, 90, 90 90, 90, 120 90, 90, 90
Resolution (A˚) 46.95-1.57 (1.66-1.57) 87.8-2.51 (2.64-2.51) 44.77-1.88 (1.98-1.88)
No. of unique reflections 42810 (5989) 13039 (1868) 21548 (2703)
CC(1/2) 99.8 (56.1) 99.5 (79.3) 99.8 (74.3)
Rmeas (%) 14.4 (183.7) 18.7 (102.9) 11.2 (95.1)
Average I/sI 11.1 (1.0) 12.6 (2.7) 11.2 (2.1)
Completeness (%) 98.6 (95.5) 99.9 (99.4) 97.4 (85.6)
Multiplicity 9.7 (9.5) 10.9 (10.8) 5.7 (5.3)
Wilson B-factor 15.3 22.5 25.3
Rwork/Rfree(%) 19.5/22.6 20.0/25.4 18.6/22.6
average B-factor (A˚2) 14.9 15.6 21.8
R.m.s. deviations
Bond lengths (A˚) 0.020 0.016 0.019
Bond angles (˚) 1.968 1.869 1.994
No. Atoms (except H)
Protein 2213 2001 2049
Water 228 57 88
Residues in allowed regions 99.1 98.8 99.2
(%) of Ramachandran plot
PDB entry 4W6Y 4W6W 4W6X
aRmeas5 Sh (nh/nh-1) Sl |Ihl - ,Ih.|/Sh Sl ,Ih., where nh 5 the number of observations for reflection h,Ihl
5 the intensity for observation l of reflection h, and ,Ih. 5 the average intensity for reflection h.
bStatistics for outer resolution shell are given in parenthesis.
cRwork 5 Shkl ||Fobs | - |Fcalc ||/Shkl |Fobs |.
dRfree is defined as above but calculated for 5% of randomly chosen reflections that were excluded from the
refinement.
doi:10.1371/journal.pone.0114691.t001
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Ethics statement
Animal vaccination and experimentation was performed in strict accordance with
good animal practices, following the EU animal welfare legislation and after
approval of the local ethical committees [Committee for the Use of Laboratory
Animals at the Vrije Universiteit Brussel and the Committee of the Faculty of
Veterinary Medicine at the Universiteit Gent (EC 2014/02)]. Every effort was
made to minimize animal suffering.
Accession numbers
Atomic coordinates and structure factors have been deposited in the Protein Data
Bank as identifiers 4W6W, 4W6X and 4W6Y.
Results
Nanobodies efficiently inhibit attachment of F18 fimbriated
bacteria to piglet enterocytes in vitro
A purified truncate (residues 15–165) of the FedF tipadhesin (FedF15–165)
corresponding to the N-terminal lectin domain, where the binding capability to
blood group type 1 antigens was shown to reside [17], was used to generate
specific nanobodies [35]. Despite the smaller size of nanobodies compared to
conventional antibodies they confer high affinity and antigen specificity, high
stability and solubility, and are easy and inexpensive to produce [36]. A llama was
immunized with FedF15–165 and specific nanobodies were selected by panning the
immune library, derived from the llama peripheral blood lymphocytes, in two
consecutive rounds using the phage display technology [21]. In total twelve
nanobodies specific for FedF15–165 were obtained and further used to screen for
their inhibitory capacity in an in vitro adherence assay on piglet enterocytes. The
wild type E. coli strain 107/86 expressing F18 fimbriae [14] was incubated with
each of the twelve different nanobodies and then added to the villi of piglets. The
amount of bacteria adhering to the villi lining were counted, the results are
summarized in Fig. 1 and showed that three categories of nanobodies could be
distinguished. The adherence of the first group of nanobodies (NbFedF2,
NbFedF3, NbFedF4, NbFedF8 and NbFedF11) remains unchanged compared to
the control sample without added nanobody. In a second category, binding was
reduced compared to wild type binding but still residual binding to the piglets
enterocytes remained (NbFedF1, NbFedF5 and NbFedF10). A third group of
nanobodies leads to the (near) complete loss of attachment of the wild type strain
107/86 to piglet villi (NbFedF6, NbFedF7, NbFedF9 and NbFedF12). Sequence
alignment of these four inhibitory nanobodies reveals great sequence variability
between them in all three complementary determining regions (S1 Figure),
hinting that varying epitopes are recognized by these nanobodies. Microscale
thermophoresis was used to determine the in solution affinity between FedF15–165
and the four inhibitory nanobodies (Fig. 2). Nanobodies NbFedF6, NbFedF7,
Inhibitory Nanobodies against F18 Fimbriae
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NbFedF9 and NbFedF12 recognize FedF with low nanomolar affinity (Kd’s of
3.57, 5.25, 1.58 and 29.02 nM, respectively), which is up to a thousand fold higher
affinity in comparison with the interaction between FedF and the natural
occurring glycan ligand blood group A type 1 hexasaccharide (2.9 mM) [17]. In
the next sections we further characterized the three best inhibiting nanobodies
(NbFedF6, NbFedF7 and NbFedF9) by X-ray crystallography.
Nanobody NbFedF9 inhibits attachment by steric occlusion of the
FedF carbohydrate binding site
Crystallization trials of the NbFedF9-FedF15–165 co-complex were set up in order
to obtain structural information about the inhibitory mechanism of NbFedF9.
These efforts resulted in the elucidation of the FedF15–165- NbFedF9 structure to a
resolution of 1.5 angstrom using molecular replacement with the earlier
determined apo-FedF15–165 structure (PDB identifier 4B4P). NbFedF9 interacts
along the side of the FedF immunoglobulin-like fold (Fig. 3 left) by exclusively
hydrogen bond formation, either directly by the interaction between residues of
both NbFedF9 and FedF15–165 or indirectly with intermediary water molecules (S2
Figure). All but one of the interactions between NbFedF9 and FedF15–165 are
governed by CDR3, which is more expanded in nanobodies compared to their
VHVL antibody counterpart. Important direct interactions that stabilize the
complex are hydrogen bonds between the side chains of His88 (FedF) and Tyr114
(NbFedF9), Arg117 (FedF) and Glu101 (NbFedF9), Glu122 (FedF) and Arg112
Fig. 1. Blocking the attachment of F18 positive E. coli to piglet enterocytes by nanobodies. Nanobodies directed against the N-terminal domain of the
FedF tipadhesin (FedF15–165) were assayed in an in vitro adherence test of wild type F18-positive E. coli strain 107/86 to piglet intestinal enterocytes. As a
negative control PBS buffer was added instead of nanobody. Bacterial cells adhering to villi were counted under a microscope and plotted as a percentage
of wild type binding.
doi:10.1371/journal.pone.0114691.g001
Inhibitory Nanobodies against F18 Fimbriae
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(NbFedF9), Glu96 (FedF) and Arg108 (NbFedF9) (S2 Figure). As well two direct
interactions involving only main chain atoms are formed, more precisely between
the amide group of Ile94 (FedF) and the carboxyl group of Arg108 (NbFedF9) and
between the carboxyl group of Gly92 (FedF) and the amide group of Ser110
(NbFedF9) (S2 Figure). When the structure of the previously elucidated co-
complex between FedF15–165 and the blood group A type 1 hexasaccharide (A6-
1)[17] is overlaid on the NbFedF9-FedF15–165 complex it shows clearly how the
binding sites for the glycan A6-1 and NbFedF9 on the surface of FedF are
overlapping (Fig. 3 right; S3 Figure). Amino acid residues His88 and Arg117 on
the FedF surface have been shown to be crucial in mediating the attachment of
F18-fimbriated bacteria towards enterocytes in a mutational study [17]. In the
FedF- NbFedF9 crystal structure these residues are involved in the formation of
hydrogen bonds with NbFedF9 and thus unable to interact with the A6-1 ligand
Fig. 2. Inhibitory nanobodies recognize FedF15–165 with low nanomolar affinity. Microscale thermophoresis (MST) was employed to determine the in
solution affinity between Nb-FedF6, Nb-FedF7, Nb-FedF9 and Nb-FedF12 with FedF15–165. (A) Typical MST measurement showing the interaction between
Nb-FedF6 and FedF15–165. Data points are indicated by black diamonds, the fit by the NT Analysis software is shown as a red line. (B) Overview on the
determined dissociation constants (KD) for the indicated Nb-FedF15–165 interactions.
doi:10.1371/journal.pone.0114691.g002
Inhibitory Nanobodies against F18 Fimbriae
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(Fig. 3; S3 Figure). All together the presented co-complex structure demonstrates
how NbFedF9 inhibits the attachment of F18 fimbriated E. coli to villi by directly
competing with the carbohydrate binding site on the surface of FedF.
Nanobodies NbFedF6 and NbFedF7 inhibit attachment by inducing
local conformational changes in FedF
Crystal structures of the complexes between FedF15–165 and both NbFedF6 and
NbFedF7 were as well obtained to a resolution of respectively 2.5 A˚ and 1.7 A˚
(Fig. 4). In both elucidated complexes the nanobodies are occupying an
overlapping epitope formed by strands D9 and D0 at the interface between the two
b-sheets of FedF (Fig. 4). Nearly all interactions between NbFedF6 and FedF are
mediated by the CDR3 loop. In the NbFedF7-FedF complex the contribution of
CDR3 to the total binding affinity is even more pronounced as the other CDRs are
not involved in any direct hydrogen bond formation at all. Direct hydrogen bond
interactions that stabilize the NbFedF6-FedF15–165 complex are Arg45 (NbFedF6)
and Ala96 (FedF), Ser54 (NbFedF6) and Gln84 (FedF), Phe100 (NbFedF6) and
both Gly92/Asn81 (FedF), Tyr102 (NbFedF6) and Asn81 (FedF), Gln109
(NbFedF6) and both Gly98/Ala96 (FedF), Ala110 (NbFedF6) and Gly94 (FedF)
Fig. 3. NbFedF9 inhibits the binding of F18 fimbriated E. coli to piglet enterocytes by occupying the carbohydrate binding site on the FedF
surface. Left: structure of the complex between the inhibitory NbFedF9 (green) and FedF15–165 (b-strands, a-helices and loops are colored respectively
cyan, red and grey), which shows NbFedF9 interacting at the side of the FedF fold. The three complementary determining regions (CDRs) of NbFedF9 are
colored respectively in orange, purple and yellow. Right: overlay of the NbFedF9-FedF15–165 structure with the previously elucidated structure of the co-
complex between FedF15-165 and the blood group A type 1 hexasaccharide [17]. Both the carbohydrate ligand and NbFedF9 compete for the same binding
site on the FedF fold. Blood group A type 1 hexasaccharide is depicted in stick model with carbon, oxygen and nitrogen atoms colored respectively purple,
red and blue.
doi:10.1371/journal.pone.0114691.g003
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(S4 Figure). In the NbFedF7-FedF complex Trp111 is inserted in a deep
hydrophobic groove on the FedF surface with optimal shape complementary and
as well forms a direct interaction with Ser79; other important interactions are
Ser100 (NbFedF7) and Thr46 (FedF), Asn101 (NbFedF7) and both Asn81/Gly92
(FedF), Ser102 (NbFedF7) and Gln91 (FedF), Ala110 (NbFedF7) and Gly94
(FedF), Asn113 (NbFedF7) and Ser44 (FedF) (S4 Figure). Although a near
identical epitope is targeted by NbFedF6 and NbFedF7 they differ significantly in
the sequence of their CDR3 loop (S1 Figure) and the residues involved in the
recognition of the epitope on the FedF surface. Both nanobody NbFedF6 and
NbFedF7 are interacting distant from the A6-1 binding site (Fig. 5), thus contrary
to the inhibitory complex between FedF- NbFedF9 in which NbFedF9 directly
competed with the blood group antigen binding site. When superimposing the
crystal structures of the FedF-A6-1 complex with the NbFedF6/7-FedF complex it
shows how both nanobodies induce a conformational change in the D0-E loop
(Fig. 5). The D0-E loop is displaced more outwards relative to the A6-1 binding
site by the CDR3 loop of the nanobody and thereby pushed slightly upwards
relative to the FedF surface. The conformation of none of the amino acid residues
identified in our earlier study to interact with the A6-1 ligand is affected
significantly [17]. To confirm that both nanobodies can still bind the ligand we
Fig. 4. Overview of the binding of inhibitory nanobodies NbFedF6 and NbFedF7 on the surface of the F18 fimbrial adhesin FedF. Nanobodies
NbFedF6 and NbFedF7 (green) are interacting with a near identical epitope at the interface of the two b-sheets that make up the immunoglobulin-like fold of
FedF15–165 (b-strands, a-helices and loops are colored respectively cyan, red and grey). The three complementary determining regions (CDRs) are colored
respectively in orange, purple and yellow.
doi:10.1371/journal.pone.0114691.g004
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performed an inhibition experiment using surface plasmon resonance. FedF was
mixed with a fixed concentration of the different inhibitory nanobodies and
injected over a chip on which a human serum albumine-A6-1 glycoconjugate was
immobilized. As could be expected NbFedF9 completely abolished the binding of
FedF with A6-1 (Fig 6). On the contrary when adding an excess of nanobodies
NbFedF6 and NbFedF7, and as well nanobody NbFedF12, FedF was still able to
fully or partially interact with the A6-1-HSA glycoconjugate (Fig. 6), and in
addition these nanobodies are not altering the binding kinetics of the interaction.
These results demonstrate the conformational change induced by the nanobodies
NbFedF6 and NbFedF7 cannot completely explain their inhibitory capacity. This
is despite their full binding inhibition in a biological context, when FedF is
binding membrane-embedded sphingolipids. The D0-E loop harbors two
positively charged lysine residues that we identified previously to add non-specific
binding affinity in proximity to the membrane [17]. By targeting this loop and
changing its conformation we could thus block the affinity of F18 fimbriated
bacteria towards membrane imbedded glycosphingolipid receptors. Either this
inhibitory effect stems from the disruption of the conformation of the critical D0-
E loop, or another possibility that cannot be excluded is that NbFedF6 and
NbFedF7 upon binding impart steric hindrance with the nearby phospholipid
bilayer.
Fig. 5. Conformational change induced inhibition of adhesion by nanobodies NbFedF6 and NbFedF7. Superimposition of the FedF-blood group A
type 1 hexasaccharide (A6-1) co-complex structure (colored yellow) with the co-complex structures of FedF-NbFedF6 (A) and FedF-NbFedF7 (B) (b-
strands, a-helices and loops are colored respectively cyan, red and grey). Both NbFedF6 and NbFedF7 induce a conformational change in the D0-E loop
that is protruding from the FedF surface thereby reorienting the loop outwards from the A6-1 binding site. A6-1 is depicted in stick model with carbon, oxygen
and nitrogen atoms colored respectively purple, red and blue.
doi:10.1371/journal.pone.0114691.g005
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Discussion
Adhesion of pathogens to receptors presented on the host tissue is the first crucial
step in the initiation of infection. Often this goal is attained by hair-like surface
organelles termed fimbriae or pili that enable the bacteria to reach distant located
receptors without the immediate need for cell-cell contact. Enterotoxigenic E. coli
and Shiga toxin producing E. coli strains causing respectively post-weaning
diarrhoea and edema disease are important pathogenic strains and cause massive
havoc in livestock. In order to infect piglets these strains express the F18 fimbriae
on their cell surface that interacts via the two-domain FedF tipadhesin with ABO
blood group type 1 determinants presented on glycosphingolipids. The molecular
details on the FedF-blood group antigen interaction have been unraveled and
directed mutagenesis together with in vitro binding assays demonstrated a
polybasic D0-E loop adjacent to the carbohydrate binding site is required for to
Fig. 6. Nanobodies that induce a conformational change in the D0-E loop do not inhibit the attachment of FedF towards the A6-1 carbohydrate.
Consecutive injections of either FedF15–165 or FedF15–165-nanobody complexes over the sensor chip surface carrying an immobilized A6-1-human serum
albumin glycoconjugate were performed. Nanobody NbFedF9, shown in the crystal structure to bind in the FedF carbohydrate binding site, completely
blocks the FedF-A6-1 interaction. In contrary, nanobodies NbFedF6, NbFedF7 and NbFedF12 only slightly or not at all inhibit the binding of FedF on the A6-
1 coated surface. The crystal structures show how NbFedF6 and NbFedF7 induce a conformational change in the D0-E loop but do not steric compete with
A6-1 binding.
doi:10.1371/journal.pone.0114691.g006
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the FedF–glycosphingolipid interaction in proximity of the lipid bilayer [17]. The
D0-E loop was proposed to direct selectivity towards membrane-associated blood
group determinants and thus evades the binding to soluble glycoproteins that
contain ABH blood group antigens, and are present in mucosal secretions. In this
study we generated nanobodies that could block the attachment of F18 fimbriated
E. coli cells to piglet villi in an in vitro cell binding assay. The co-complex crystal
structures revealed the inhibitory action of these nanobodies, either they steric
compete with the blood group antigen binding site on the FedF surface
(NbFedF9) or they induced a conformational change in the crucial D0-E loop
(NbFedF6, NbFedF7 and NbFedF12). This result highlights the importance of the
critical D0-E loop in mediating attachment of F18 fimbriae with membrane
localized receptors, although steric hindrance with the near membrane bilayer
cannot be left out.
The FedF adhesin is highly conserved in isolates from different countries [37],
and none of the amino acid variability within these isolates coincides with the
epitope recognized by the different inhibiting nanobodies. Since these epitopes are
highly conserved the nanobodies we described can be broadly used over different
countries to neutralize the binding of F18 fimbriated ETEC and STEC strains on
the villi of piglets and alleviate the symptoms caused by these infections. Oral
administration of purified antibodies to the intestinal tract can be limited by the
harsh acidic environment of the stomach [38]. In Virdi et al. (2013) we showed
protection of weaned piglets by oral passive immunization with anti-F4 fimbriae
nanobodies fused to the Fc domain of pig IgA by producing these fusion
antibodies in A. thaliana seeds and administrating these crushed seeds as a feed
supplement [39]. During transit through the gastrointestinal tract these fusion
nanobodies are protected and can functionally realize their protective effect as
evidenced by a progressive decline in shedding of F4-positive bacteria, a
significantly lower immune response to F4 fimbriae and a higher weight gain
compared to piglets in the non-treated control group [39]. It is anticipated that
the anti-FedF nanobodies described in this paper can in a similar way be grafted to
the Fc domain of pig IgA and produced in plant seeds to act as prophylactic
agents. Both F4 and F18 positive strains have a high prevalence in post-weaning E.
coli infections in piglets. The most effective protection against ETEC and STEC
infections is therefore expected to come from passive immunization regimens that
combine both anti-F4 and anti-FedF Fc fused nanobodies. F4 fimbriae have their
adhesive capability build into the polymerizing subunit, resulting in the exposure
of several hundreds of interaction sites across the fimbrial length. In contrast F18
fimbriae have a single tip-adhesin FedF that confers binding properties and thus
less interaction surfaces need to be blocked to obtain a protective effect.
The usage of fusion nanobodies has a number of advantages over more
conventional prophylactic treatments, like the use of vaccines [18] or small
molecule compounds. Initially the generation of transgenic plants is labor
intensive and costly, but afterwards production will be inexpensive and
straightforward. Nanobodies feature a high affinity towards their respective
antigens, whereas organic compounds often require several intensive rounds of
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structure-based chemical optimization to attain a reasonable binding affinity.
Anti-adhesives designed against the FimH adhesin of type 1 pili, involved in the
disease process of uropathogenic E. coli, show low nanomolar binding affinities
[40–42] and were shown to be effective in an in vivo murine model upon oral
administration [43]. FimH is however exceptional as it features a deeply buried
mannose binding pocket that exhibits nanomolar binding strength towards its
natural carbohydrate ligands [44]. Difficulties arise when targeting more open,
shallow binding grooves as in the case for the PapG adhesin from P pili that are
involved in adherence to the kidney epithelium, thereby causing pyelonephritis
[45]. The most potent multivalent PapG inhibitor to date has an IC50 value of
only 2 mM [46, 47]. The majority of hitherto obtained crystal structures, including
FedF, fall into this last class that possess shallow carbohydrate binding grooves
and the macroscopic binding affinity of bacteria stems from the combined avidity
of individual weak interactions. Together these observations indicate the problems
associated with the approach of designing anti-adhesive organic compounds [48].
Nanobodies circumvent the long tedious and repetitive process of developing
optimized small molecule anti-adhesives and will in a short time span result in
nanomolar binding tools that block the unwanted attachment of bacterial lectins
to host tissue.
In conclusion, we have generated and characterized four nanobodies that
interfere with F18 fimbriae mediated attachment. The inhibitory mechanism has
been unraveled and demonstrates the nanobodies directly compete with the blood
group antigen binding site or induce a conformational change in the polybasic D0-
E loop. These nanobodies will in the near future be expressed in plant seeds to act
as a prophylactic agent to reduce the burden of ETEC and STEC infections in
intensive pig farming.
Supporting Information
S1 Figure. Sequence alignment of the four nanobodies that inhibit attachment
of F18 positive E. coli with piglet villi in vitro. Residues are colored according to
the sequence variability between the nanobody sequences, with residues colored
blue being the highest conserved and residues colored red exhibit the least
conservancy. The three complementary determining regions (CDR) are indicated
by green bars and named. Alignment was generated using CLC workbench.
doi:10.1371/journal.pone.0114691.s001 (TIF)
S2 Figure. Details on the interaction site of NbFedF9 and FedF15–165. NbFedF9
(yellow) binds at the side of the FedF fold (grey) and interacts solely by the
formation of hydrogen bonds. Either direct hydrogen bonds (dashed lines,
colored red) are formed by residues of both NbFedF9 and FedF15–165 or indirectly
by an intermediary water molecule (dashed lines, orange). Amino acid residues
involved in the interaction are named and indicated by either a black (NbFedF9)
or dark blue (FedF) label. Water molecules are depicted as spheres and colored
green. Interacting main chain and side chain atoms are depicted in stick
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representation with oxygen and nitrogen atoms colored respectively in red and
blue.
doi:10.1371/journal.pone.0114691.s002 (TIF)
S3 Figure. NbFedF9 directly competes with the sugar binding site on the FedF
surface. Shown is a comparison of the binding site of blood group A type 1
hexasaccharide (A6-1) (left) and NbFedF9 (right) on the FedF surface. Residues
His88 and Arg117 can be seen to interact both with NbFedF9 and A6-1, and these
residues are named. FedF is depicted in cartoon representation and colored gray,
whereas NbFedF9 and A6-1 are depicted in cartoon and stick representations,
respectively, and colored yellow. Interacting residues are shown in stick model
with oxygen and nitrogen atoms colored red and blue, respectively. Hydrogen
bonds are highlighted as red dotted lines.
doi:10.1371/journal.pone.0114691.s003 (TIF)
S4 Figure. Details on the interaction between FedF15–165 and NbFedF6 or
NbFedF7 that induce a conformational change in the D0-E loop. NbFedF6
(A)(B) and NbFedF7 (C)(D) are colored yellow and interact at the interface
between the two b-sheets of the immunoglobulin-like fold of FedF (grey). Direct
hydrogen bonds (dashed lines, colored red) are formed by residues of both
nanobodies and FedF15–165 or indirect hydrogen bonds by a connecting
intermediary water molecule (dashed lines, orange). Amino acid residues involved
in the interaction are named and indicated by either a black (nanobodies) or dark
blue (FedF) label. Water molecules are depicted as spheres and colored green.
Interacting main chain and side chain atoms are depicted in stick representation
with oxygen and nitrogen atoms colored respectively in red and blue.
doi:10.1371/journal.pone.0114691.s004 (TIF)
S5 Figure. Electron density maps of the interface of the different FedF15–165-
nanobody complexes. Electron density map at 1.6 sigma of the interaction
interface of the FedF15–165-NbFedF6, FedF15–165-NbFedF7 and FedF15–165-
NbFedF9 complexes.
doi:10.1371/journal.pone.0114691.s005 (TIF)
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